Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00311
|
|||||
| Drug Name |
Ambrisentan
|
|||||
| Synonyms |
(+-)-(2S)-2-((4,6-Dimethylpyrimidin-2-yl)oxy)-3-methoxy-3,3-diphenylpropanoic acid; 2-(4,6-dimethylpyrimidin-2-yl)oxy-3-methoxy-3,3-diphenyl-propanoic acid; 2-(4,6-dimethylpyrimidin-2-yl)oxy-3-methoxy-3,3-diphenylpropanoic acid; 2-[(4,6-dimethylpyrimidin-2-yl)oxy]-3-methoxy-3,3-diphenylpropanoic acid; Ambrisentan [INN]; BSF 208075; BSF-208075; BSF208075; Benzenepropanoic acid, .alpha.-[(4,6-dimethyl-2-pyrimidinyl)oxy]-.beta.-methoxy-.beta.-phe; Gilead brand of ambrisentan; LU 208075; LU-208075; LU208075; Letairis
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Pulmonary arterial hypertension [ICD11:BB01.0] | Approved | [1] | |||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C22H22N2O4
|
|||||
| Canonical SMILES |
CC1=CC(=NC(=N1)OC(C(=O)O)C(C2=CC=CC=C2)(C3=CC=CC=C3)OC)C
|
|||||
| InChI |
InChI=1S/C22H22N2O4/c1-15-14-16(2)24-21(23-15)28-19(20(25)26)22(27-3,17-10-6-4-7-11-17)18-12-8-5-9-13-18/h4-14,19H,1-3H3,(H,25,26)/t19-/m1/s1
|
|||||
| InChIKey |
OUJTZYPIHDYQMC-LJQANCHMSA-N
|
|||||
| CAS Number |
CAS 177036-94-1
|
|||||
| Pharmaceutical Properties | Molecular Weight | 378.4 | Topological Polar Surface Area | 81.5 | ||
| Heavy Atom Count | 28 | Rotatable Bond Count | 7 | |||
| Hydrogen Bond Donor Count | 1 | Hydrogen Bond Acceptor Count | 6 | |||
| XLogP |
3.8
|
|||||
| PubChem CID | ||||||
| PubChem SID |
103307060
,104035299
,114788055
,118855302
,12015371
,126616865
,126651844
,131302629
,134338642
,135692418
,137237404
,139988399
,143497715
,144205520
,14779987
,152133959
,152238501
,152258462
,160647297
,160826914
,162011508
,162172038
,163093066
,163387054
,164824132
,170465143
,17194924
,174007223
,175267375
,175426501
,178100778
,179116973
,185986582
,187071933
,196107821
,198977886
,198991664
,204430246
,211534802
,223375980
,223532574
,223704800
,224518792
,226395806
,43529863
,50551569
,51091419
,53787770
,57371956
,93309673
|
|||||
| ChEBI ID |
CHEBI:135949
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [2] | |
| References | ||||||
| 1 | Ambrisentan was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Potential for pharmacokinetic interactions between ambrisentan and cyclosporine. Clin Pharmacol Ther. 2010 Oct;88(4):513-20. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.